

Shaoguang Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5334971/publications.pdf>

Version: 2024-02-01

43
papers

892
citations

687363

13
h-index

477307

29
g-index

43
all docs

43
docs citations

43
times ranked

1561
citing authors

#	ARTICLE	IF	CITATIONS
1	Differential m6A RNA landscapes across hematopoiesis reveal a role for IGF2BP2 in preserving hematopoietic stem cell function. <i>Cell Stem Cell</i> , 2022, 29, 149-159.e7.	11.1	49
2	An artificial intelligence deep learning platform achieves high diagnostic accuracy for Covid-19 pneumonia by reading chest X-ray images. <i>IScience</i> , 2022, 25, 104031.	4.1	11
3	YBX1 is required for maintaining myeloid leukemia cell survival by regulating <i>BCL2</i> stability in an m6A-dependent manner. <i>Blood</i> , 2021, 138, 71-85.	1.4	87
4	Therapeutic inhibition of Fc γ RIIb signaling targets leukemic stem cells in chronic myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2635-2647.	7.2	8
5	A deep learning diagnostic platform for diffuse large B-cell lymphoma with high accuracy across multiple hospitals. <i>Nature Communications</i> , 2020, 11, 6004.	12.8	51
6	Leukemogenic Chromatin Alterations Promote AML Leukemia Stem Cells via a KDM4C-ALKBH5-AXL Signaling Axis. <i>Cell Stem Cell</i> , 2020, 27, 81-97.e8.	11.1	140
7	Leukemia Stem Cells in Chronic Myeloid Leukemia. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1143, 191-215.	1.6	7
8	Prosurvival kinase PIM2 is a therapeutic target for eradication of chronic myeloid leukemia stem cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 10482-10487.	7.1	10
9	Concise Review: Exploiting Unique Biological Features of Leukemia Stem Cells for Therapeutic Benefit. <i>Stem Cells Translational Medicine</i> , 2019, 8, 768-774.	3.3	5
10	Good Tolerance and Durable Remission for Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Refractory/Relapsed Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 2818-2818.	1.4	1
11	Activation of JAK2/STAT5 Pathway Reduces Expression Level of DNMT3a in MPN Cell Line. <i>Blood</i> , 2019, 134, 5394-5394.	1.4	0
12	Patients with Bone and Bone Marrow Involvement Had Better OS and PFS in Patients with Aggressive Non-Hodgkin Lymphoma Treated with CD19 CART T Cells. <i>Blood</i> , 2019, 134, 5315-5315.	1.4	0
13	Clinical Presentation, Management and Biomarkers of Cytokine Release Syndrome after Anti-CD19 CART-Cell Therapy for r/r ALL. <i>Blood</i> , 2019, 134, 5625-5625.	1.4	0
14	Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine. <i>Blood</i> , 2017, 130, 655-665.	1.4	63
15	<i>Alox5</i> Blockade Eradicates JAK2V617F-Induced Polycythemia Vera in Mice. <i>Cancer Research</i> , 2017, 77, 164-174.	0.9	10
16	Chronic Myeloid Leukemia (CML) Mouse Model in Translational Research. <i>Methods in Molecular Biology</i> , 2016, 1438, 225-243.	0.9	12
17	Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1. <i>Blood</i> , 2016, 127, 1803-1813.	1.4	24
18	Novel oral transforming growth factor β signaling inhibitor EW7197 eradicates CML-initiating cells. <i>Cancer Science</i> , 2016, 107, 140-148.	3.9	28

#	ARTICLE	IF	CITATIONS
19	Induction of Chronic Myeloid Leukemia in Mice. <i>Methods in Molecular Biology</i> , 2016, 1465, 17-25.	0.9	4
20	Chronic Myelogenous Leukemiaâ€™s Initiating Cells Require Polycomb Group Protein EZH2. <i>Cancer Discovery</i> , 2016, 6, 1237-1247.	9.4	72
21	Timing of the loss of Pten protein determines disease severity in a mouse model of myeloid malignancy. <i>Blood</i> , 2016, 127, 1912-1922.	1.4	15
22	Fighting fat in AML. <i>Blood</i> , 2016, 128, 1910-1911.	1.4	0
23	Survival regulation of leukemia stem cells. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 1039-1050.	5.4	31
24	The Src kinases Hck, Fgr, and Lyn activate Abl2/Arg to facilitate IgG-mediated phagocytosis and <i>Leishmania</i> infection. <i>Journal of Cell Science</i> , 2016, 129, 3130-43.	2.0	18
25	Targeting Chronic Myeloid Leukemia Stem Cells through Pharmacological Inhibition of HIF-1 α . <i>Blood</i> , 2016, 128, 4235-4235.	1.4	0
26	Inhibition of CML Stem Cells with an Alkaloid That Reduces β -Catenin. <i>Blood</i> , 2016, 128, 1882-1882.	1.4	0
27	Leukemic marrow infiltration reveals a novel role for Egr3 as a potent inhibitor of normal hematopoietic stem cell proliferation. <i>Blood</i> , 2015, 126, 1302-1313.	1.4	93
28	A therapeutically targetable mechanism of BCR-ABLâ€™s independent imatinib resistance in chronic myeloid leukemia. <i>Science Translational Medicine</i> , 2014, 6, 252ra121.	12.4	105
29	Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia. <i>OncoTargets and Therapy</i> , 2014, 7, 177.	2.0	14
30	Management and orphan drug development for acute myeloid leukemia. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 441-451.	0.8	0
31	PKC Pathways Mediate BCR-ABL-Independent Imatinib Resistance in Chronic Myeloid Leukemia. <i>Blood</i> , 2014, 124, 1790-1790.	1.4	21
32	Genetic Depletion of Fc Gamma Receptor 2b Affects CML Stem Cell Biology. <i>Blood</i> , 2014, 124, 4528-4528.	1.4	1
33	Eradication of Chronic Myelogenous Leukemia By Inactivation of the Polycomb Group Protein EZH2. <i>Blood</i> , 2014, 124, 778-778.	1.4	1
34	Timing of the Loss of Pten Is Critical in Determining the Disease Phenotype in Mice- a Mouse Model for Pediatric Mixed MDS/MPN. <i>Blood</i> , 2014, 124, 3585-3585.	1.4	0
35	DNA Microarray Assay Helps to Identify Functional Genes Specific for Leukemia Stem Cells. <i>Dataset Papers in Science</i> , 2013, 2013, 1-5.	1.0	1
36	PRKD2 Serine-Threonine Kinase, an Essential Effector of Gabp Transcription Factor, Is Required for Development of Chronic Myelogenous Leukemia. <i>Blood</i> , 2012, 120, 1672-1672.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Nfkb1 Plays a Tumor-Suppressing Role in BCR-ABL-Induced Leukemias. Blood, 2012, 120, 1666-1666.	1.4	0
38	Without GABP Transcription Factor, BCR-ABL Cannot Transform HSCs to Leukemic Stem Cells Nor Induce Chronic Myelogenous Leukemia in Mice. Blood, 2011, 118, 965-965.	1.4	7
39	HIF1 α Is Required for Survival Maintenance of Chronic Myeloid Leukemia Stem Cells. Blood, 2011, 118, 449-449.	1.4	0
40	The Scd1 Gene Functions as a Tumor Suppressor In Leukemia Stem Cells. Blood, 2010, 116, 201-201.	1.4	3
41	The Tumor Suppressor Role of the Msr1 Gene in Cancer Stem Cells of Chronic Myeloid Leukemia.. Blood, 2009, 114, 188-188.	1.4	0
42	Beta-catenin Is Essential for Survival of Leukemia Stem Cells Insensitive to Kinase Inhibition in Mice with BCR-ABL Induced Chronic Myeloid Leukemia.. Blood, 2008, 112, 1080-1080.	1.4	0
43	Distinct Gab2-Mediated Signaling Pathways Are Essential for Myeloid or Lymphoid Transformation and Leukemogenesis by BCR-ABL. Blood, 2008, 112, 570-570.	1.4	0